Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | The emerging role of vaccines such as Nous-209 in cancer interception

Eduardo Vilar, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of using vaccines for cancer interception, and highlights the Nous-209 vaccine for prevention of mismatch repair deficient pre-cancers and cancers in Lynch Syndrome carriers. Vaccines hold great promise in cancer interception for these populations, offering a potential preventive approach. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.